- Email: [email protected]
Neoadjuvant Therapy in Advanced Ovarian Cancer Patients: Efficiency of Screening By Laparoscopy for Clinical Trial Recruitment
Annals of Oncology 25 (Supplement 4): iv305–iv326, 2014 doi:10.1093/annonc/mdu338.22
gynaecological cancers 897P
NEOADJUVANT THERAPY IN ADVANCED OVARIAN CANCER PATIENTS: EFFICIENCY OF SCREENING BY LAPAROSCOPY FOR CLINICAL TRIAL RECRUITMENT
abstracts
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_4/iv313/2241612 by guest on 24 October 2019
R. Rouzier1, E. Chereau2, A. Floquet3, F. Selle4, V. Fourchotte5, C. Pomel6, P. Follana7, S. Martin-Françoise8, R. Fauvet9, P. Colombo10, E. Kalbacher11, A. Lesoin12, F. Lécuru13, P.H. Cottu14, F. Joly Lobbedez15, V. Menguy16, Y. Ghazi16, P. Morice17 1 Department of Surgery, Institut Curie-Université Versailles-Saint-Quentin, Paris-Saint-Cloud, FRANCE 2 Surgery, Institut Paoli Calmette, Marseille, FRANCE 3 Oncologie, Institut Bergonié, Bordeaux, FRANCE 4 Medical Oncology, Hôpital Tenon, Paris, FRANCE 5 Department of Surgery, Institut Curie, Paris, FRANCE 6 Surgery, Centre Jean Perrin, Clermont-Ferrand, FRANCE 7 Medical Oncology, Centre Antoine Lacassagne, Nice, FRANCE 8 Medical Oncology, Centre Francois Baclesse, Caen, FRANCE 9 Obstetrics Gynecology, CHU, Amiens, FRANCE 10 Surgery, Institut de Cancérologie Montpellier, Montpellier, FRANCE 11 Franche Comté, CHRU Besancon, Besancon, FRANCE 12 Medical Oncology, Centre Oscar Lambret, Lille, FRANCE 13 Gynecologic Surgery, Hôpital Européen Georges Pompidou, Paris, FRANCE 14 Medical Oncology, Institut Curie, Paris, FRANCE 15 Medical Oncology, Centre Francois Baclesse, Caen, FRANCE 16 Gynecologic Oncology, Roche, Boulogne, FRANCE 17 Surgery, Institut Gustave Roussy, Villejuif, FRANCE
Aim: There is an important literature supporting the role of staging laparoscopy to predict the chances of optimal cytoreduction but its role to screen patient for inclusion in neoadjuvant therapy clinical trial is unknown. We report here the results of screening by laparoscopy for inclusion in a clinical trial testing the efficacy of bevacizumab in the neoadjuvant settting (Anthalya: A Randomized, Open-label, Phase II Study Assessing the Efficacy and the Safety of Bevacizumab in Neoadjuvant Therapy in Patients With FIGO Stage IIIC/IV Ovarian, Tubal or Peritoneal Adenocarcinoma, Initially Unresectable. NCT01739218). Methods: We are currently conducting a clinical trial to evaluate the efficacy of neoadjuvant bevacizumab and chemotherapy measured by the rate of complete resection, defined as the removal of all macroscopic residual tumour at interval debulking surgery (IDS). Secondary objectives are: safety, Objective Response Rate for the neoadjuvant period and after all courses of treatment and monitoring of CA 125. Before randomization, patients with suspicion of stage IIIC-IV ovarian cancer had a laparoscopy to have a histological assessment of the tumor, to document the FIGO stage and to evaluate resectability for inclusion. Standard pictures and scoring are performed during this laparoscopy and during IDS. We report here the results of screening by laparoscopy. Results: This multicenter study is conducted in 14 centers. Over a 16 month period, 182 and 82 patients have been screened and randomized, respectively. The proportion of screening/inclusion in the paticipating centers ranged from 16% to 100% (mean: 46%). Reasons for non inclusion were resectable tumor (60%), non ovarian/tubal/ peritoneal adenocarcinoma histology or contra-indication to carboplatin/taxol/ bevacizumab (29%), patient refusal (1%). The screening success was not statistically related to the specialty of the PI in each center (medical oncologist vs surgical oncologist, p = 0.09) or to the volume of patients screened ( p = 0.09). Conclusions: In patients with suspicion of ovarian cancer (based on imaging, CA125 and clinical data), screening by laparoscopy resulted in eligibility of 46% of patients for inclusion in a neoadjuvant therapy clinical trial. Resectable tumors was the first reason for non inclusion in this neoadjuvant therapy trial. Disclosure: R. Rouzier: membership on an advisory board; V. Menguy: Employee;Y. Ghazi: Employee;. All other authors have declared no conflicts of interest.
© European Society for Medical Oncology 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
gynaecological cancers 897P
NEOADJUVANT THERAPY IN ADVANCED OVARIAN CANCER PATIENTS: EFFICIENCY OF SCREENING BY LAPAROSCOPY FOR CLINICAL TRIAL RECRUITMENT
abstracts
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_4/iv313/2241612 by guest on 24 October 2019
R. Rouzier1, E. Chereau2, A. Floquet3, F. Selle4, V. Fourchotte5, C. Pomel6, P. Follana7, S. Martin-Françoise8, R. Fauvet9, P. Colombo10, E. Kalbacher11, A. Lesoin12, F. Lécuru13, P.H. Cottu14, F. Joly Lobbedez15, V. Menguy16, Y. Ghazi16, P. Morice17 1 Department of Surgery, Institut Curie-Université Versailles-Saint-Quentin, Paris-Saint-Cloud, FRANCE 2 Surgery, Institut Paoli Calmette, Marseille, FRANCE 3 Oncologie, Institut Bergonié, Bordeaux, FRANCE 4 Medical Oncology, Hôpital Tenon, Paris, FRANCE 5 Department of Surgery, Institut Curie, Paris, FRANCE 6 Surgery, Centre Jean Perrin, Clermont-Ferrand, FRANCE 7 Medical Oncology, Centre Antoine Lacassagne, Nice, FRANCE 8 Medical Oncology, Centre Francois Baclesse, Caen, FRANCE 9 Obstetrics Gynecology, CHU, Amiens, FRANCE 10 Surgery, Institut de Cancérologie Montpellier, Montpellier, FRANCE 11 Franche Comté, CHRU Besancon, Besancon, FRANCE 12 Medical Oncology, Centre Oscar Lambret, Lille, FRANCE 13 Gynecologic Surgery, Hôpital Européen Georges Pompidou, Paris, FRANCE 14 Medical Oncology, Institut Curie, Paris, FRANCE 15 Medical Oncology, Centre Francois Baclesse, Caen, FRANCE 16 Gynecologic Oncology, Roche, Boulogne, FRANCE 17 Surgery, Institut Gustave Roussy, Villejuif, FRANCE
Aim: There is an important literature supporting the role of staging laparoscopy to predict the chances of optimal cytoreduction but its role to screen patient for inclusion in neoadjuvant therapy clinical trial is unknown. We report here the results of screening by laparoscopy for inclusion in a clinical trial testing the efficacy of bevacizumab in the neoadjuvant settting (Anthalya: A Randomized, Open-label, Phase II Study Assessing the Efficacy and the Safety of Bevacizumab in Neoadjuvant Therapy in Patients With FIGO Stage IIIC/IV Ovarian, Tubal or Peritoneal Adenocarcinoma, Initially Unresectable. NCT01739218). Methods: We are currently conducting a clinical trial to evaluate the efficacy of neoadjuvant bevacizumab and chemotherapy measured by the rate of complete resection, defined as the removal of all macroscopic residual tumour at interval debulking surgery (IDS). Secondary objectives are: safety, Objective Response Rate for the neoadjuvant period and after all courses of treatment and monitoring of CA 125. Before randomization, patients with suspicion of stage IIIC-IV ovarian cancer had a laparoscopy to have a histological assessment of the tumor, to document the FIGO stage and to evaluate resectability for inclusion. Standard pictures and scoring are performed during this laparoscopy and during IDS. We report here the results of screening by laparoscopy. Results: This multicenter study is conducted in 14 centers. Over a 16 month period, 182 and 82 patients have been screened and randomized, respectively. The proportion of screening/inclusion in the paticipating centers ranged from 16% to 100% (mean: 46%). Reasons for non inclusion were resectable tumor (60%), non ovarian/tubal/ peritoneal adenocarcinoma histology or contra-indication to carboplatin/taxol/ bevacizumab (29%), patient refusal (1%). The screening success was not statistically related to the specialty of the PI in each center (medical oncologist vs surgical oncologist, p = 0.09) or to the volume of patients screened ( p = 0.09). Conclusions: In patients with suspicion of ovarian cancer (based on imaging, CA125 and clinical data), screening by laparoscopy resulted in eligibility of 46% of patients for inclusion in a neoadjuvant therapy clinical trial. Resectable tumors was the first reason for non inclusion in this neoadjuvant therapy trial. Disclosure: R. Rouzier: membership on an advisory board; V. Menguy: Employee;Y. Ghazi: Employee;. All other authors have declared no conflicts of interest.
© European Society for Medical Oncology 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].